The	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
APC	I-Disease
)	I-Disease
tumour	I-Disease
-	O
suppressor	O
protein	O
controls	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O

Like	O
APC	O
,	O
APC2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin	O
-	O
Tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC	O
-	O
/	O
-	O
colon	B-Disease
carcinoma	I-Disease
cells	O
.	O

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	B-Disease
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O

The	O
frequency	O
,	O
origin	O
,	O
and	O
phenotypic	O
expression	O
of	O
a	O
germline	O
MSH2	O
gene	O
mutation	O
previously	O
identified	O
in	O
seven	O
kindreds	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
cancer	I-Disease
syndrome	I-Disease
(	O
HNPCC	B-Disease
)	O
was	O
investigated	O
.	O

In	O
contrast	O
,	O
the	O
MSH2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	O
colorectal	B-Disease
families	O
from	O
Newfoundland	O
.	O

These	O
findings	O
suggested	O
a	O
founder	O
effect	O
within	O
Newfoundland	O
similar	O
to	O
that	O
reported	O
by	O
others	O
for	O
two	O
MLH1	O
mutations	O
in	O
Finnish	O
HNPCC	B-Disease
families	O
.	O

The	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
males	O
than	O
females	O
(	O
0	O
.	O
63	O
v	O
0	O
.	O
30	O
and	O
0	O
.	O
84	O
v	O
0	O
.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O

For	O
females	O
there	O
was	O
a	O
high	O
risk	O
of	O
endometrial	B-Disease
cancer	I-Disease
(	O
0	O
.	O
5	O
at	O
age	O
60	O
years	O
)	O
and	O
premenopausal	B-Disease
ovarian	I-Disease
cancer	I-Disease
(	O
0	O
.	O
2	O
at	O
50	O
years	O
)	O
.	O

Age	O
of	O
onset	O
(	O
AO	O
)	O
of	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	B-Disease
gene	O
.	O

Apolipoprotein	O
E	O
(	O
APOE	O
)	O
genotype	O
,	O
in	O
turn	O
,	O
is	O
known	O
to	O
influence	O
AO	O
in	O
Alzheimer	B-Disease
disease	I-Disease
,	O
rendering	O
the	O
APOE	O
gene	O
a	O
likely	O
candidate	O
to	O
affect	O
AO	O
in	O
other	O
neurological	B-Disease
diseases	I-Disease
too	O
.	O

Our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B-Disease
in	O
HD	B-Disease
may	O
allow	O
interacting	O
genes	O
to	O
exert	O
gender	O
specific	O
effects	O
upon	O
AO	O
.	O

Familial	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
associated	O
with	O
recurrent	O
bacteremic	B-Disease
infections	I-Disease
due	I-Disease
to	I-Disease
Neisseria	I-Disease
.	O

The	O
absence	B-Disease
of	I-Disease
functional	I-Disease
C7	I-Disease
activity	O
could	O
not	O
be	O
accounted	O
for	O
on	O
the	O
basis	O
of	O
an	O
inhibitor	O
.	O

This	O
report	O
represents	O
the	O
first	O
cases	O
of	O
C7	B-Disease
deficiency	I-Disease
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	B-Disease
neisseria	I-Disease
infections	I-Disease
.	O

OBJECTIVE	O
Previous	O
reports	O
have	O
suggested	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
among	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
(	O
CHH	B-Disease
)	O
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	O
among	O
patients	O
with	O
CHH	B-Disease
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

This	O
cohort	O
underwent	O
follow	O
-	O
up	O
for	O
cancer	B-Disease
incidence	O
through	O
the	O
Finnish	O
Cancer	O
Registry	O
to	O
the	O
end	O
of	O
1995	O
.	O

The	O
cancer	B-Disease
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B-Disease
incidence	O
in	O
the	O
Finnish	O
population	O
.	O

CONCLUSIONS	O
This	O
study	O
confirms	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
,	O
especially	O
non	B-Disease
-	I-Disease
Hodgkins	I-Disease
lymphoma	I-Disease
,	O
probably	O
attributable	O
to	O
defective	O
immunity	O
,	O
among	O
patients	O
with	O
CHH	B-Disease
.	O

In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
DPD	B-Disease
deficiency	I-Disease
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	B-Disease
of	I-Disease
DPD	I-Disease
.	O

A	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed	O
,	O
with	O
convulsive	B-Disease
disorders	I-Disease
,	O
motor	B-Disease
retardation	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
being	O
the	O
most	O
abundant	O
manifestations	O
.	O

An	O
altered	O
beta	O
-	O
alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	B-Disease
abnormalities	I-Disease
encountered	O
in	O
patients	O
with	O
DPD	B-Disease
deficiency	I-Disease
.	O

We	O
have	O
identified	O
a	O
male	O
patient	O
with	O
BFLS	B-Disease
-	O
like	O
features	O
and	O
a	O
duplication	O
,	O
46	O
,	O
Y	O
,	O
dup	O
(	O
X	O
)	O
(	O
q26q28	O
)	O
,	O
inherited	O
from	O
his	O
phenotypically	O
normal	O
mother	O
.	O

The	O
FHF2	O
gene	O
localisation	O
and	O
tissue	O
-	O
specific	O
expression	O
pattern	O
suggest	O
it	O
to	O
be	O
a	O
candidate	O
gene	O
for	O
familial	O
cases	O
of	O
the	O
BFLS	B-Disease
syndrome	I-Disease
and	O
other	O
syndromal	O
and	O
non	O
-	O
specific	O
forms	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
mapping	O
to	O
the	O
region	O
.	O

Familial	B-Disease
gastric	I-Disease
cancer	I-Disease
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	B-Disease
cancer	I-Disease
susceptibility	O
in	O
non	O
-	O
Maori	O
populations	O
is	O
due	O
to	O
germline	O
CDH1	O
mutations	O
.	O

Therefore	O
,	O
we	O
screened	O
eight	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
kindreds	O
of	O
British	O
and	O
Irish	O
origin	O
for	O
germline	O
CDH1	O
mutations	O
,	O
by	O
SSCP	O
analysis	O
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences	O
.	O

In	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non	O
-	O
penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancer	I-Disease
;	O
thus	O
,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
,	O
a	O
CDH1	O
mutation	O
carrier	O
developed	O
colorectal	B-Disease
cancer	I-Disease
at	O
age	O
30	O
years	O
.	O

Loss	O
of	O
E	O
-	O
cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	B-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
CDH1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	B-Disease
cancer	I-Disease
.	O

Thus	O
,	O
CDH1	O
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancers	I-Disease
.	O

The	O
analysis	O
of	O
diseases	O
linked	O
specifically	O
with	O
WT1	O
mutations	O
,	O
such	O
as	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	B-Disease
)	O
,	O
can	O
provide	O
valuable	O
insight	O
concerning	O
the	O
role	O
of	O
WT1	O
in	O
development	O
and	O
disease	O
.	O

DDS	B-Disease
is	O
a	O
rare	O
childhood	O
disease	O
characterized	O
by	O
a	O
nephropathy	B-Disease
involving	O
mesangial	B-Disease
sclerosis	I-Disease
,	O
XY	O
pseudohermaphroditism	B-Disease
,	O
and	O
/	O
or	O
Wilms	B-Disease
tumor	I-Disease
(	O
WT	B-Disease
)	O
.	O

We	O
report	O
that	O
heterozygosity	O
for	O
a	O
targeted	O
murine	O
Wt1	O
allele	O
,	O
Wt1	O
(	O
tmT396	O
)	O
,	O
which	O
truncates	O
ZF3	O
at	O
codon	O
396	O
,	O
induces	O
mesangial	B-Disease
sclerosis	I-Disease
characteristic	O
of	O
DDS	B-Disease
in	O
adult	O
heterozygous	O
and	O
chimeric	O
mice	O
.	O

Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1	O
.	O

Hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption	O
.	O

Neurophysiologic	O
follow	O
-	O
up	O
of	O
long	O
-	O
term	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
.	O

OBJECTIVE	O
To	O
monitor	O
the	O
effects	O
of	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
by	O
means	O
of	O
somatosensory	O
evoked	O
potentials	O
(	O
SEPs	O
)	O
and	O
motor	O
evoked	O
potentials	O
(	O
MEPs	O
)	O
.	O

Three	O
of	O
these	O
patients	O
had	O
pure	O
spinal	B-Disease
SEP	I-Disease
abnormalities	I-Disease
and	O
in	O
the	O
remaining	O
two	O
patients	O
SEPs	O
showed	O
signs	O
of	O
involvement	O
of	O
both	O
the	O
spinal	O
and	O
cerebral	O
somatosensory	O
tracts	O
.	O

After	O
treatment	O
,	O
the	O
three	O
patients	O
with	O
pure	O
spinal	B-Disease
abnormalities	I-Disease
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
,	O
whereas	O
the	O
two	O
patients	O
with	O
a	O
more	O
advanced	O
stage	O
of	O
disease	O
(	O
exhibited	O
by	O
SEPs	O
)	O
showed	O
substantially	O
unchanged	O
clinical	O
and	O
neurophysiologic	O
features	O
.	O

GCH1	O
mutation	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
.	O

Germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
Korean	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
.	O

We	O
extensively	O
analyzed	O
genomic	O
DNA	O
and	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
from	O
62	O
unrelated	O
Korean	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
for	O
identification	O
of	O
germline	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
mutations	O
.	O

Our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
PTT	O
was	O
superior	O
to	O
that	O
with	O
SSCP	O
,	O
and	O
suggest	O
that	O
PTT	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
FAP	B-Disease
patients	O
.	O

Molecular	O
epidemiology	O
of	O
C9	B-Disease
deficiency	I-Disease
heterozygotes	O
with	O
an	O
Arg95Stop	O
mutation	O
of	O
the	O
C9	O
gene	O
in	O
Japan	O
.	O

An	O
estimated	O
frequency	O
(	O
0	O
.	O
12	O
%	O
)	O
of	O
complete	O
C9	B-Disease
deficiency	I-Disease
due	O
to	O
homozygous	O
Arg95Stop	O
mutation	O
was	O
consistent	O
with	O
frequencies	O
determined	O
by	O
serological	O
studies	O

The	O
hereditary	B-Disease
hemochromatosis	I-Disease
protein	O
,	O
HFE	O
,	O
specifically	O
regulates	O
transferrin	O
-	O
mediated	O
iron	O
uptake	O
in	O
HeLa	O
cells	O
.	O

Mutation	O
and	O
haplotype	O
studies	O
of	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	O
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O

Nevertheless	O
,	O
E148Q	O
helps	O
account	O
for	O
recessive	O
inheritance	O
in	O
an	O
Ashkenazi	O
family	O
previously	O
reported	O
as	O
an	O
unusual	O
case	O
of	O
dominantly	O
inherited	O
FMF	B-Disease
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
is	O
a	O
disorder	B-Disease
of	I-Disease
lymphocyte	I-Disease
homeostasis	I-Disease
and	I-Disease
immunological	I-Disease
tolerance	I-Disease
.	O

Two	O
missense	O
Fas	O
variants	O
,	O
not	O
restricted	O
to	O
patients	O
with	O
ALPS	B-Disease
,	O
were	O
identified	O
.	O

Mutations	O
causing	O
disruption	O
of	O
the	O
intracellular	O
Fas	O
death	O
domain	O
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
ALPS	B-Disease
phenotype	O
features	O
in	O
mutation	O
-	O
bearing	O
relatives	O
.	O

Thus	O
,	O
the	O
location	O
of	O
mutations	O
within	O
APT1	O
strongly	O
influences	O
the	O
development	O
and	O
the	O
severity	O
of	O
ALPS	B-Disease
.	O

Genetic	B-Disease
hemochromatosis	I-Disease
(	O
GH	B-Disease
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry	O
.	O

In	O
northwestern	O
Europe	O
,	O
>	O
80	O
%	O
of	O
GH	B-Disease
patients	O
are	O
homozygous	O
for	O
one	O
mutation	O
,	O
the	O
substitution	O
of	O
tyrosine	O
for	O
cysteine	O
at	O
position	O
282	O
(	O
C282Y	O
)	O
in	O
the	O
unprocessed	O
protein	O
.	O

We	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(	O
DBS	O
)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
Scandinavia	O
for	O
mutations	O
in	O
HFE	O
,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	B-Disease
.	O

Alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
,	O
an	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O

Non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
associated	O
with	O
enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
is	O
caused	O
by	O
PDS	B-Disease
mutations	O
.	O

In	O
the	O
present	O
study	O
,	O
seven	O
mutations	O
in	O
the	O
PDS	B-Disease
gene	O
(	O
PDS	O
)	O
,	O
the	O
gene	O
responsible	O
for	O
Pendred	B-Disease
syndrome	I-Disease
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
EVA	B-Disease
.	O

Mutational	O
analysis	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
.	O

The	O
classic	O
form	O
of	O
ALD	B-Disease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
)	O
,	O
with	O
rapid	O
neurologic	B-Disease
deterioration	I-Disease
leading	O
to	O
a	O
vegetative	O
state	O
.	O

Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B-Disease
and	O
Addison	B-Disease
disease	I-Disease
only	O
also	O
have	O
been	O
recognized	O
.	O

METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
.	O

RESULTS	O
Three	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O

The	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations	O
,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ALD	B-Disease
gene	O
.	O

One	O
of	O
the	O
target	O
genes	O
for	O
beta	O
-	O
catenin	O
/	O
TCF	O
encodes	O
c	O
-	O
MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B-Disease
,	O
particularly	O
in	O
the	O
colon	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-Disease
tumours	I-Disease
resembling	O
pilomatricomas	B-Disease
.	O

Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B-Disease
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O

At	O
least	O
75	O
%	O
of	O
these	O
tumours	B-Disease
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	B-Disease
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta	O
-	O
catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
.	O

Pendred	B-Disease
syndrome	I-Disease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-Disease
deafness	I-Disease
and	O
characterized	O
by	O
congenital	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
and	O
goitre	B-Disease
.	O

Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B-Disease
syndrome	I-Disease
.	O
.	O

HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	B-Disease
probands	O
:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O

Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B-Disease
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	O
HH	B-Disease
chromosomes	O
.	O

The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	B-Disease
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
HH	B-Disease
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation	O
.	O

This	O
enrichment	O
of	O
S65C	O
among	O
HH	B-Disease
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
more	O
accurate	O
frequency	O
estimates	O
of	O
breast	B-Disease
cancer	I-Disease
susceptibility	O
gene	O
1	O
(	O
BRCA1	O
)	O
germline	O
alterations	O
in	O
the	O
ovarian	B-Disease
cancer	I-Disease
population	O
.	O

This	O
is	O
the	O
first	O
population	O
-	O
based	O
ovarian	B-Disease
cancer	I-Disease
study	O
reporting	O
BRCA1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region	O
.	O

Both	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

The	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
Caucasian	O
cancer	B-Disease
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele	O
-	O
specific	O
amplification	O
.	O

Adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-Disease
protein	I-Disease
deficiency	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
:	O
implications	O
for	O
therapy	O
.	O

Inherited	B-Disease
defects	I-Disease
in	O
the	O
peroxisomal	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
adrenoleukodystrophy	B-Disease
protein	O
(	O
ALDP	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B-Disease
disorder	I-Disease
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	B-Disease
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

Mutant	O
fibroblasts	O
contain	O
multiple	O
,	O
functional	O
centrosomes	O
,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation	O
,	O
abnormal	O
nuclear	O
division	O
,	O
and	O
aneuploidy	B-Disease
.	O

Heterozygous	O
mutations	O
in	O
the	O
CD95	O
(	O
APO	O
-	O
1	O
/	O
Fas	O
)	O
receptor	O
occur	O
in	O
most	O
individuals	O
with	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism	O
.	O

Despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele	O
,	O
lymphocytes	O
from	O
ALPS	B-Disease
patients	O
showed	O
markedly	O
decreased	O
FADD	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking	O
.	O

Analysis	O
of	O
alkaptonuria	B-Disease
(	O
AKU	B-Disease
)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
CCC	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	B-Disease
pedigrees	O
.	O

Fabry	B-Disease
disease	I-Disease
:	O
identification	O
of	O
novel	O
alpha	O
-	O
galactosidase	O
A	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches	O
.	O

Fabry	B-Disease
disease	I-Disease
(	O
FD	B-Disease
)	O
(	O
angiokeratoma	B-Disease
corporis	I-Disease
diffusum	I-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
inborn	I-Disease
error	I-Disease
of	I-Disease
glycosphingolipid	I-Disease
metabolism	I-Disease
caused	O
by	O
defects	O
in	O
the	O
lysosomal	O
alpha	O
-	O
galactosidase	O
A	O
gene	O
(	O
GLA	O
)	O
.	O

While	O
demonstration	O
of	O
alpha	B-Disease
-	I-Disease
galactosidase	I-Disease
deficiency	I-Disease
in	O
leukocytes	O
is	O
diagnostic	O
in	O
affected	O
males	O
,	O
enzymatic	O
detection	O
of	O
female	O
carriers	O
is	O
often	O
inconclusive	O
,	O
due	O
to	O
random	O
X	O
-	O
chromosomal	O
inactivation	O
,	O
underlining	O
the	O
need	O
of	O
molecular	O
investigations	O
for	O
accurate	O
genetic	O
counseling	O
.	O

A	O
diagnosis	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
MIM	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	O
boy	O
.	O

The	O
proband	O
was	O
found	O
to	O
carry	O
the	O
duplication	O
,	O
thus	O
confirming	O
the	O
diagnosis	O
of	O
Pelizaeus	B-Disease
Merzbacher	I-Disease
disease	I-Disease
,	O
but	O
neither	O
the	O
aunt	O
nor	O
the	O
fetus	O
carried	O
a	O
duplication	O
.	O
.	O

Inactivation	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O

Together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
APC	B-Disease
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B-Disease
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B-Disease
mutants	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B-Disease
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B-Disease
.	O

Wild	O
-	O
type	O
APC	B-Disease
activity	O
in	O
beta	O
-	O
catenin	O
-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B-Disease
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O

These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
FAP	B-Disease
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B-Disease
tumor	I-Disease
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
.	O

Combined	B-Disease
genetic	I-Disease
deficiency	I-Disease
of	I-Disease
C6	I-Disease
and	I-Disease
C7	I-Disease
in	O
man	O
.	O

No	O
clinical	O
disease	O
was	O
associated	O
with	O
this	O
deficiency	O
which	O
was	O
transmitted	O
through	O
the	O
subjects	O
family	O
as	O
a	O
single	O
genetic	O
characteristic	O
,	O
the	O
C6	B-Disease
deficiency	I-Disease
being	O
associated	O
with	O
a	O
silent	O
allele	O
at	O
the	O
structural	O
locus	O
.	O

Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
muscular	I-Disease
dystrophy	I-Disease
characterized	O
by	O
early	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
,	I-Disease
Achilles	I-Disease
tendons	I-Disease
and	I-Disease
spine	I-Disease
,	O
slowly	O
progressive	O
muscle	B-Disease
wasting	I-Disease
and	O
weakness	B-Disease
,	O
and	O
cardiomyopathy	B-Disease
associated	O
with	O
cardiac	B-Disease
conduction	I-Disease
defects	I-Disease
.	O

In	O
comparison	O
with	O
the	O
usual	O
EDMD	B-Disease
phenotype	O
,	O
patients	O
with	O
P183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms	O
,	O
elbow	B-Disease
contractures	I-Disease
,	O
ankle	B-Disease
contractures	I-Disease
,	O
upper	B-Disease
limb	I-Disease
weakness	I-Disease
and	O
lower	B-Disease
limb	I-Disease
weakness	I-Disease
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	B-Disease
involvement	I-Disease
.	O

This	O
is	O
the	O
first	O
report	O
of	O
protein	O
studies	O
on	O
patients	O
with	O
missense	O
mutations	O
resulting	O
in	O
the	O
clinical	O
features	O
of	O
EDMD	B-Disease
.	O

Along	O
with	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
and	O
lip	B-Disease
pits	I-Disease
,	O
affected	O
relatives	O
exhibit	O
developmental	B-Disease
delays	I-Disease
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted	O
.	O

In	O
this	O
family	O
,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
VWS	B-Disease
.	O

Splicing	O
defects	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
,	O
ATM	O
:	O
underlying	O
mutations	O
and	O
consequences	O
.	O

Mutations	O
resulting	O
in	O
defective	O
splicing	O
constitute	O
a	O
significant	O
proportion	O
(	O
30	O
/	O
62	O
[	O
48	O
%	O
]	O
)	O
of	O
a	O
new	O
series	O
of	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
AT	B-Disease
)	O
that	O
were	O
detected	O
by	O
the	O
protein	O
-	O
truncation	O
assay	O
followed	O
by	O
sequence	O
analysis	O
of	O
genomic	O
DNA	O
.	O

We	O
identified	O
the	O
alpha	O
-	O
cardiac	O
actin	O
gene	O
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
(	O
FHC	B-Disease
)	O
.	O

Linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
FHC	B-Disease
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied	O
,	O
with	O
lod	O
scores	O
varying	O
between	O
-	O
2	O
.	O

Overgrowth	B-Disease
of	I-Disease
oral	I-Disease
mucosa	I-Disease
and	I-Disease
facial	I-Disease
skin	I-Disease
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B-Disease
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	B-Disease
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O

Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B-Disease
of	I-Disease
the	I-Disease
facial	I-Disease
skin	I-Disease
already	O
common	O
in	O
childhood	O
.	O

Of	O
44	O
patients	O
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B-Disease
angiofibromas	I-Disease
,	O
tumours	B-Disease
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	B-Disease
sclerosis	I-Disease
.	O

Immunohistochemically	O
,	O
expression	O
of	O
AGA	O
in	O
AGU	B-Disease
patients	O
mucosal	B-Disease
lesions	I-Disease
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O

Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	B-Disease
syndrome	I-Disease
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene	O
.	O

We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	B-Disease
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in	O
-	O
frame	O
deletion	O
.	O

MEFV	O
-	O
Gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
:	O
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
M694V	O
homozygous	O
genotype	O
-	O
genetic	O
and	O
therapeutic	O
implications	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessively	B-Disease
inherited	I-Disease
disorder	I-Disease
that	O
is	O
common	O
in	O
patients	O
of	O
Armenian	O
ancestry	O
.	O

Renal	B-Disease
amyloidosis	I-Disease
,	O
prevented	O
by	O
colchicine	O
,	O
is	O
the	O
most	O
severe	O
complication	O
of	O
FMF	B-Disease
,	O
a	O
disorder	O
associated	O
with	O
mutations	O
in	O
the	O
MEFV	O
gene	O
.	O

The	O
M694V	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	B-Disease
amyloidosis	I-Disease
and	O
arthritis	B-Disease
,	O
compared	O
with	O
other	O
genotypes	O
(	O
P	O
=	O
.	O
0002	O
and	O
P	O
=	O
.	O
006	O
,	O
respectively	O
)	O
.	O

Noninvasive	O
test	O
for	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
using	O
hair	O
root	O
analysis	O
.	O

Here	O
we	O
describe	O
a	O
new	O
diagnostic	O
test	O
to	O
identify	O
male	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
on	O
the	O
basis	O
of	O
lack	O
of	O
FMRP	O
in	O
their	O
hair	O
roots	O
.	O

Expression	O
of	O
FMRP	O
in	O
hair	O
roots	O
was	O
studied	O
by	O
use	O
of	O
an	O
FMRP	O
-	O
specific	O
antibody	O
test	O
,	O
and	O
the	O
percentage	O
of	O
FMRP	O
-	O
expressing	O
hair	O
roots	O
in	O
controls	O
and	O
in	O
male	O
fragile	B-Disease
X	I-Disease
patients	O
was	O
determined	O
.	O

The	O
advantages	O
of	O
this	O
test	O
are	O
(	O
1	O
)	O
plucking	O
of	O
hair	O
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	B-Disease
retarded	I-Disease
patient	O
,	O
(	O
2	O
)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	O
center	O
,	O
and	O
(	O
3	O
)	O
the	O
result	O
of	O
the	O
test	O
is	O
available	O
within	O
5	O
h	O
of	O
plucking	O
.	O

In	O
addition	O
,	O
this	O
test	O
enabled	O
us	O
to	O
identify	O
two	O
fragile	B-Disease
X	I-Disease
patients	O
who	O
did	O
not	O
show	O
the	O
full	O
mutation	O
by	O
analysis	O
of	O
DNA	O
isolated	O
from	O
blood	O
cells	O
.	O
.	O

We	O
previously	O
reported	O
evidence	O
of	O
linkage	O
to	O
the	O
1q24	O
-	O
25	O
region	O
(	O
HPC1	O
)	O
in	O
91	O
North	O
American	O
and	O
Swedish	O
families	O
each	O
with	O
multiple	O
cases	O
of	O
prostate	B-Disease
cancer	I-Disease
(	O
Smith	O
et	O
al	O
.	O
1996	O
)	O
.	O

In	O
the	O
present	O
report	O
we	O
analyze	O
40	O
(	O
12	O
original	O
and	O
28	O
newly	O
identified	O
)	O
Swedish	O
families	O
with	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
(	O
HPC	B-Disease
)	O
that	O
,	O
on	O
the	O
basis	O
of	O
40	O
markers	O
spanning	O
a	O
25	O
-	O
cM	O
interval	O
within	O
1q24	O
-	O
25	O
,	O
have	O
evidence	O
of	O
linkage	O
.	O

Molecular	O
basis	O
of	O
feline	O
beta	B-Disease
-	I-Disease
glucuronidase	I-Disease
deficiency	I-Disease
:	O
an	O
animal	O
model	O
of	O
mucopolysaccharidosis	B-Disease
VII	I-Disease
.	O

Carriers	O
identified	O
in	O
this	O
manner	O
produced	O
affected	O
kittens	O
in	O
prospective	O
breedings	O
,	O
and	O
a	O
feline	O
MPS	B-Disease
VII	I-Disease
breeding	O
colony	O
has	O
been	O
established	O
.	O
.	O

Three	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
,	O
cat	B-Disease
-	I-Disease
eye	I-Disease
syndrome	I-Disease
,	O
der	B-Disease
(	I-Disease
)	I-Disease
syndrome	I-Disease
and	O
velo	B-Disease
-	I-Disease
cardio	I-Disease
-	I-Disease
facial	I-Disease
syndrome	I-Disease
/	O
DiGeorge	B-Disease
syndrome	I-Disease
(	O
VCFS	B-Disease
/	O
DGS	B-Disease
)	O
are	O
associated	O
with	O
tetrasomy	O
,	O
trisomy	O
or	O
monosomy	O
,	O
respectively	O
,	O
for	O
part	O
of	O
chromosome	O
22q11	O
.	O

VCFS	B-Disease
/	O
DGS	B-Disease
is	O
the	O
most	O
common	O
syndrome	O
associated	O
with	O
22q11	O
rearrangements	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
developed	O
hamster	O
-	O
human	O
somatic	O
hybrid	O
cell	O
lines	O
from	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	O
within	O
similar	O
low	O
copy	O
repeats	O
,	O
termed	O
LCR22s	O
.	O

We	O
present	O
models	O
to	O
explain	O
how	O
the	O
LCR22s	O
can	O
mediate	O
different	O
homologous	O
recombination	O
events	O
,	O
thereby	O
generating	O
a	O
number	O
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
.	O

Functional	O
consequences	O
of	O
mutations	O
in	O
the	O
early	O
growth	O
response	O
2	O
gene	O
(	O
EGR2	O
)	O
correlate	O
with	O
severity	O
of	O
human	O
myelinopathies	B-Disease
.	O

Mutations	O
in	O
the	O
human	O
EGR2	O
gene	O
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	B-Disease
peripheral	I-Disease
neuropathies	I-Disease
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
type	I-Disease
1	I-Disease
,	O
Dejerine	B-Disease
-	I-Disease
Sottas	I-Disease
syndrome	I-Disease
and	O
congenital	B-Disease
hypomyelinating	I-Disease
neuropathy	I-Disease
.	O

Familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
post	O
-	O
natal	O
development	O
of	O
arginine	B-Disease
vasopressin	I-Disease
(	I-Disease
AVP	I-Disease
)	I-Disease
deficiency	I-Disease
due	O
to	O
mutations	O
in	O
the	O
AVP	O
gene	O
.	O

We	O
studied	O
an	O
unusual	O
Palestinian	O
family	O
consisting	O
of	O
asymptomatic	O
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	O
with	O
neurohypophyseal	B-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
suggesting	O
autosomal	O
recessive	O
inheritance	O
.	O

No	O
inherited	O
form	O
of	O
GPI	B-Disease
-	I-Disease
anchor	I-Disease
deficiency	I-Disease
has	O
been	O
described	O
.	O

Because	O
conventional	O
Piga	O
gene	O
knockout	O
is	O
associated	O
with	O
high	O
embryonic	B-Disease
lethality	I-Disease
in	O
chimeric	O
mice	O
,	O
we	O
used	O
the	O
Cre	O
/	O
loxP	O
system	O
.	O

Targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	B-Disease
gene	O
(	O
Hfe	O
)	O
locus	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
identification	O
of	O
a	O
missense	O
mutation	O
associated	O
with	O
a	O
milder	O
phenotype	O
.	O

Age	O
at	O
onset	O
was	O
later	O
for	O
first	O
symptoms	O
and	O
for	O
development	O
of	O
ankle	B-Disease
contractures	I-Disease
and	O
muscle	B-Disease
weakness	I-Disease
.	O

Severe	O
clinical	O
expression	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

The	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
.	O

Common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
do	O
not	O
contribute	O
to	O
early	O
prostate	B-Disease
cancer	I-Disease
in	O
Jewish	O
men	O
.	O

METHODS	O
We	O
examined	O
genomic	O
DNA	O
from	O
83	O
(	O
for	O
BRCA1	O
185delAG	O
)	O
or	O
82	O
(	O
for	O
BRCA2	O
6174delT	O
)	O
Ashkenazi	O
Jewish	O
prostate	B-Disease
cancer	I-Disease
patients	O
,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	O
age	O
,	O
for	O
the	O
most	O
common	O
germline	O
mutation	O
in	O
each	O
gene	O
seen	O
in	O
the	O
Ashkenazi	O
population	O
.	O

RESULTS	O
Our	O
study	O
should	O
have	O
been	O
able	O
to	O
detect	O
a	O
4	O
-	O
5	O
-	O
fold	O
increase	O
in	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
due	O
to	O
mutation	O
of	O
BRCA1	O
or	O
BRCA2	O
.	O

Beta	O
-	O
catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B-Disease
.	O

Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B-Disease
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O

In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta	O
-	O
catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B-Disease
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
,	O
we	O
observed	O
increased	O
beta	O
-	O
catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-Disease
.	O

Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta	O
-	O
catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-Disease
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	B-Disease
type	O
.	O

Hereditary	B-Disease
progressive	I-Disease
dystonia	I-Disease
with	O
marked	O
diurnal	O
fluctuation	O
(	O
HPD	B-Disease
;	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
,	O
DRD	B-Disease
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
the	O
GTP	O
cyclohydrolase	O
I	O
(	O
GCH1	O
)	O
gene	O
.	O

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B-Disease
syndrome	I-Disease
thyrocytes	O
.	O

The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	B-Disease
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B-Disease
goiter	I-Disease
and	O
sensory	B-Disease
-	I-Disease
neural	I-Disease
deafness	I-Disease
remains	O
an	O
enigma	O
.	O

We	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
Pendred	B-Disease
syndrome	I-Disease
patients	O
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O

Mutations	O
in	O
the	O
gene	O
that	O
encodes	O
type	O
II	O
collagen	O
(	O
COL2A1	O
)	O
,	O
the	O
predominant	O
protein	O
of	O
cartilage	O
,	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
individuals	O
with	O
Kniest	B-Disease
dysplasia	I-Disease
.	O

Sequencing	O
of	O
the	O
index	O
patients	O
genomic	O
DNA	O
identified	O
four	O
new	O
dominant	O
mutations	O
in	O
COL2A1	O
that	O
result	O
in	O
Kniest	B-Disease
dysplasia	I-Disease
a	O
21	O
-	O
bp	O
deletion	O
in	O
exon	O
16	O
,	O
an	O
18	O
-	O
bp	O
deletion	O
in	O
exon	O
19	O
,	O
and	O
4	O
-	O
bp	O
deletions	O
in	O
the	O
splice	O
donor	O
sites	O
of	O
introns	O
14	O
and	O
20	O
.	O

Classical	B-Disease
galactosemia	I-Disease
and	O
mutations	O
at	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
gene	O
.	O

Classical	B-Disease
galactosemia	I-Disease
is	O
caused	O
by	O
a	O
deficiency	O
in	O
activity	O
of	O
the	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
caused	O
by	O
mutations	O
at	O
the	O
GALT	O
gene	O
.	O

Mutations	O
of	O
the	O
VHL	B-Disease
gene	O
in	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
:	O
definition	O
of	O
a	O
risk	O
factor	O
for	O
VHL	B-Disease
patients	O
to	O
develop	O
an	O
RCC	B-Disease
.	O

VHL	B-Disease
mutations	O
were	O
found	O
only	O
in	O
the	O
nonpapillary	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
RCC	B-Disease
)	O
subtype	O
,	O
as	O
previously	O
reported	O
.	O

We	O
postulated	O
that	O
a	O
specific	O
pattern	O
of	O
VHL	B-Disease
mutations	O
is	O
associated	O
with	O
sporadic	B-Disease
RCC	I-Disease
.	O

We	O
observed	O
RCC	B-Disease
in	O
at	O
least	O
one	O
member	O
of	O
the	O
VHL	B-Disease
families	O
in	O
77	O
%	O
of	O
cases	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
versus	O
55	O
%	O
in	O
cases	O
with	O
missense	O
mutations	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Chediak	B-Disease
-	I-Disease
Higashi	I-Disease
syndrome	I-Disease
(	O
CHS	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
trafficking	O
regulator	O
gene	O
,	O
LYST	O
.	O

The	O
murine	O
equivalent	O
of	O
CHS	B-Disease
,	O
beige	O
mice	O
,	O
present	O
similar	O
characteristics	O
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	B-Disease
syndrome	I-Disease
.	O

It	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	O
of	O
CTLA	O
-	O
4	O
by	O
CHS	B-Disease
T	O
cells	O
is	O
involved	O
in	O
the	O
generation	O
of	O
lymphoproliferative	B-Disease
disease	I-Disease
.	O

Proteolipoprotein	O
gene	O
analysis	O
in	O
82	O
patients	O
with	O
sporadic	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
Disease	I-Disease
:	O
duplications	O
,	O
the	O
major	O
cause	O
of	O
the	O
disease	O
,	O
originate	O
more	O
frequently	O
in	O
male	O
germ	O
cells	O
,	O
but	O
point	O
mutations	O
do	O
not	O
.	O

Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
Disease	I-Disease
(	O
PMD	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
developmental	I-Disease
defect	I-Disease
of	I-Disease
myelination	I-Disease
affecting	O
the	O
central	O
nervous	O
system	O
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(	O
PLP	O
)	O
locus	O
.	O

Chromosome	O
breakage	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
and	I-Disease
Angelman	I-Disease
syndromes	I-Disease
involves	O
recombination	O
between	O
large	O
,	O
transcribed	O
repeats	O
at	O
proximal	O
and	O
distal	O
breakpoints	O
.	O

Linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
family	O
with	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	O
locus	O
for	O
cleft	B-Disease
palate	I-Disease
at	O
17p11	O
.	O
2	O
-	O
11	O
.	O
1	O
.	O

van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
,	O
which	O
has	O
been	O
mapped	O
to	O
1q32	O
-	O
41	O
,	O
is	O
characterized	O
by	O
pits	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
sinuses	I-Disease
of	I-Disease
the	I-Disease
lower	I-Disease
lip	I-Disease
,	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
(	O
CL	B-Disease
/	I-Disease
P	I-Disease
)	O
,	O
cleft	B-Disease
palate	I-Disease
(	O
CP	B-Disease
)	O
,	O
bifid	B-Disease
uvula	I-Disease
,	O
and	O
hypodontia	B-Disease
(	O
H	B-Disease
)	O
.	O

Both	O
the	O
occurrence	O
of	O
CL	B-Disease
/	I-Disease
P	I-Disease
and	O
CP	B-Disease
within	O
the	O
same	O
genealogy	O
and	O
a	O
recurrence	O
risk	O
<	O
40	O
%	O
for	O
CP	B-Disease
among	O
descendants	O
with	O
VWS	B-Disease
have	O
suggested	O
that	O
the	O
development	O
of	O
clefts	B-Disease
in	O
this	O
syndrome	O
is	O
influenced	O
by	O
modifying	O
genes	O
at	O
other	O
loci	O
.	O

1	O
,	O
together	O
with	O
the	O
VWS	B-Disease
gene	O
at	O
1p32	O
-	O
41	O
,	O
enhances	O
the	O
probability	O
of	O
CP	B-Disease
in	O
an	O
individual	O
carrying	O
the	O
two	O
at	O
-	O
risk	O
genes	O
.	O

Using	O
DNA	O
as	O
the	O
starting	O
material	O
,	O
we	O
screened	O
the	O
ATM	O
gene	O
in	O
92	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
,	O
using	O
an	O
optimized	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
that	O
detected	O
all	O
previously	O
known	O
mutations	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
segments	O
being	O
analyzed	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
XK	O
gene	O
(	O
XK	O
)	O
in	O
a	O
Japanese	O
patient	O
with	O
McLeod	B-Disease
syndrome	I-Disease
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	O
showed	O
progressive	O
muscular	B-Disease
atrophy	I-Disease
,	O
choreic	B-Disease
movement	I-Disease
,	O
elevated	O
level	O
of	O
serum	O
creatinine	O
kinase	O
,	O
and	O
acanthocytosis	B-Disease
.	O

Formation	O
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
BRCA1	O
,	O
hRad50	O
,	O
hMre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC	O
/	O
1937	O
breast	B-Disease
cancer	I-Disease
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
BRCA1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	O
-	O
type	O
BRCA1	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
(	O
PKU	B-Disease
)	O
.	O

Based	O
on	O
previous	O
knowledge	O
about	O
mutation	O
-	O
phenotype	O
associations	O
,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(	O
severe	O
PKU	B-Disease
,	O
moderate	O
PKU	B-Disease
,	O
mild	O
PKU	B-Disease
,	O
and	O
mild	B-Disease
hyperphenylalaninemia	I-Disease
[	O
MHP	B-Disease
]	O
)	O
.	O

The	O
IQ	O
of	O
PAH	B-Disease
-	I-Disease
deficient	I-Disease
mothers	O
with	O
a	O
severe	O
PKU	B-Disease
mutation	O
in	O
combination	O
with	O
a	O
MHP	B-Disease
mutation	O
or	O
a	O
mild	O
PKU	B-Disease
mutation	O
was	O
99	O
and	O
96	O
,	O
respectively	O
,	O
whereas	O
the	O
IQ	O
of	O
PKU	B-Disease
mothers	O
with	O
two	O
severe	O
PKU	B-Disease
mutations	O
or	O
with	O
one	O
severe	O
and	O
one	O
moderate	O
PKU	B-Disease
mutation	O
was	O
83	O
and	O
84	O
,	O
respectively	O
.	O

CONCLUSIONS	O
The	O
reproductive	O
outcome	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances	O
.	O

Both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
PKU	B-Disease
.	O

We	O
describe	O
seven	O
Dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive	O
,	O
mainly	O
spinal	B-Disease
cord	I-Disease
syndrome	I-Disease
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

MRI	O
demonstrated	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	O
cord	O
.	O

A	O
transgene	O
insertion	O
creating	O
a	O
heritable	O
chromosome	O
deletion	O
mouse	O
model	O
of	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
and	I-Disease
angelman	I-Disease
syndromes	I-Disease
.	O

We	O
report	O
here	O
the	O
characterization	O
of	O
a	O
transgene	O
insertion	O
(	O
Epstein	O
-	O
Barr	O
virus	O
Latent	O
Membrane	O
Protein	O
2A	O
,	O
LMP2A	O
)	O
into	O
mouse	O
chromosome	O
7C	O
,	O
which	O
has	O
resulted	O
in	O
mouse	O
models	O
for	O
PWS	B-Disease
and	O
AS	B-Disease
dependent	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

Because	O
the	O
intact	O
chromosome	O
7	O
,	O
opposite	O
the	O
deleted	O
homolog	O
,	O
maintains	O
the	O
correct	O
imprint	O
in	O
somatic	O
cells	O
of	O
PWS	B-Disease
and	O
AS	B-Disease
mice	O
and	O
establishes	O
the	O
correct	O
imprint	O
in	O
male	O
and	O
female	O
germ	O
cells	O
of	O
AS	B-Disease
mice	O
,	O
homologous	O
association	O
and	O
replication	O
asynchrony	O
are	O
not	O
part	O
of	O
the	O
imprinting	O
mechanism	O
.	O

Linkage	O
analysis	O
of	O
5	O
novel	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
kindreds	O
to	O
1q32	O
-	O
q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait	O
.	O

The	O
vWS	B-Disease
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32	O
-	O
q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping	O
.	O

Our	O
results	O
support	O
linkage	O
of	O
vWS	B-Disease
within	O
a	O
region	O
of	O
tightly	O
linked	O
markers	O
and	O
do	O
not	O
favour	O
locus	O
heterogeneity	O
of	O
the	O
disease	O
trait	O
.	O

Using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
ATP7B	O
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(	O
null	O
)	O
for	O
the	O
Wilson	B-Disease
disease	I-Disease
gene	O
.	O

An	O
increase	O
in	O
copper	O
concentration	O
was	O
also	O
observed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo	O
-	O
zygous	O
mutants	O
,	O
although	O
milk	O
from	O
the	O
mutant	O
glands	O
was	O
copper	B-Disease
deficient	I-Disease
.	O

Progeny	O
of	O
the	O
homozygous	O
mutant	O
females	O
demonstrated	O
neurological	B-Disease
abnormalities	I-Disease
and	O
growth	B-Disease
retardation	I-Disease
characteristic	O
of	O
copper	B-Disease
deficiency	I-Disease
.	O

Segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	B-Disease
repeat	I-Disease
disorders	I-Disease
.	O

On	O
the	O
basis	O
of	O
a	O
sperm	O
typing	O
study	O
performed	O
in	O
patients	O
of	O
Japanese	O
descent	O
with	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
,	O
it	O
was	O
reported	O
that	O
disease	O
alleles	O
are	O
preferentially	O
transmitted	O
during	O
meiosis	O
.	O

However	O
,	O
analysis	O
of	O
the	O
variance	O
in	O
repeat	O
number	O
in	O
sperm	O
from	O
the	O
French	O
MJD	B-Disease
patients	O
overlapped	O
significantly	O
with	O
the	O
variance	O
in	O
repeat	O
number	O
observed	O
in	O
the	O
C	O
/	O
C	O
homozygous	O
Japanese	O
patients	O
.	O

We	O
ascertained	O
a	O
novel	O
missense	O
mutation	O
in	O
four	O
pedigrees	O
with	O
Peters	B-Disease
anomaly	I-Disease
,	O
congenital	B-Disease
cataract	I-Disease
,	O
Axenfeldt	B-Disease
anomaly	I-Disease
,	O
and	O
/	O
or	O
foveal	B-Disease
hypoplasia	I-Disease
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
is	O
the	O
first	O
mutation	O
identified	O
in	O
the	O
splice	O
-	O
variant	O
region	O
.	O

Penetrances	O
of	O
BRCA1	O
1675delA	O
and	O
1135insA	O
with	O
respect	O
to	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
.	O

Index	O
cases	O
for	O
the	O
present	O
study	O
were	O
found	O
two	O
different	O
ways	O
through	O
a	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancers	I-Disease
(	O
n	O
=	O
16	O
)	O
and	O
through	O
our	O
family	O
cancer	B-Disease
clinic	O
(	O
n	O
=	O
14	O
)	O
.	O

The	O
overall	O
findings	O
were	O
that	O
disease	O
started	O
to	O
occur	O
at	O
age	O
30	O
years	O
and	O
that	O
by	O
age	O
50	O
years	O
48	O
%	O
of	O
the	O
mutation	O
-	O
carrying	O
women	O
had	O
experienced	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

Both	O
penetrance	O
and	O
expression	O
(	O
breast	B-Disease
cancer	I-Disease
vs	O
.	O
ovarian	B-Disease
cancer	I-Disease
)	O
were	O
different	O
from	O
those	O
in	O
reports	O
of	O
the	O
Ashkenazi	O
founder	O
mutations	O
.	O

